Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Cyclosporine structure-activity relationship

Loor F, Tiberghien F, Wenandy T, Didier A, Traber R (2002) Cyclosporins Structure-activity relationships for the inhibition of the human FPR1 formylpeptide receptor. J Med Chem 45 4598-4612. [Pg.428]

PR s current pharmacotherapy includes cyclosporine (an immunosuppressant that is metabolized predominantly by, and also inhibits, CYP3A4) and low-dose prednisone. In addition to the organoplatinum complex cisplatin, his oncologist wants to construct a chemotherapeutic regimen that combines an antimetabolite, a topoisomerase II inhibitor, and a mitosis inhibitor. Review the structure-activity relationships of the following five antineoplastic structures in preparation for your recommendation. [Pg.1839]

See other pages where Cyclosporine structure-activity relationship is mentioned: [Pg.377]    [Pg.2]    [Pg.23]    [Pg.24]    [Pg.31]    [Pg.297]    [Pg.198]    [Pg.415]    [Pg.202]    [Pg.273]    [Pg.321]    [Pg.196]    [Pg.232]    [Pg.127]    [Pg.605]    [Pg.323]    [Pg.355]    [Pg.873]    [Pg.873]   
See also in sourсe #XX -- [ Pg.5 , Pg.494 ]



SEARCH



Cyclosporin

Cyclosporin structure

Cyclosporin/cyclosporine

Cyclosporines

Cyclosporins

Cyclosporins Cyclosporin

© 2024 chempedia.info